| dc.contributor.author | O'Driscoll, Lorraine | en |
| dc.date.accessioned | 2017-01-19T11:00:43Z | |
| dc.date.available | 2017-01-19T11:00:43Z | |
| dc.date.issued | 2013 | en |
| dc.date.submitted | 2013 | en |
| dc.identifier.citation | Walsh N, Kennedy S, Larkin A, Corkery B, O'Driscoll L, Clynes M, Crown J, O'Donovan N., EGFR and HER2 inhibition in pancreatic cancer., Invest. New Drugs, 31, 3, 2013, 558 - 566 | en |
| dc.identifier.other | Y | en |
| dc.description | PUBLISHED | en |
| dc.format.extent | 558 | en |
| dc.format.extent | 566 | en |
| dc.language.iso | en | en |
| dc.relation.ispartofseries | Invest. New Drugs | en |
| dc.relation.ispartofseries | 31 | en |
| dc.relation.ispartofseries | 3 | en |
| dc.rights | Y | en |
| dc.title | EGFR and HER2 inhibition in pancreatic cancer. | en |
| dc.type | Journal Article | en |
| dc.type.supercollection | scholarly_publications | en |
| dc.type.supercollection | refereed_publications | en |
| dc.identifier.peoplefinderurl | http://people.tcd.ie/lodrisc | en |
| dc.identifier.rssinternalid | 92857 | en |
| dc.identifier.doi | 10.1007/s10637-012-9891-x | en |
| dc.rights.ecaccessrights | openAccess | |
| dc.relation.source | http://www.ncbi.nlm.nih.gov/pubmed/23076814 | en |
| dc.subject.TCDTheme | Cancer | en |
| dc.subject.TCDTag | Drug development and evaluation | en |
| dc.identifier.rssuri | http://www.ncbi.nlm.nih.gov/pubmed/23076814 | en |
| dc.identifier.orcid_id | 0000-0002-9860-8262 | en |
| dc.contributor.sponsor | Science Foundation Ireland (SFI) | en |
| dc.identifier.uri | http://hdl.handle.net/2262/79019 | |
